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Abstract
Background: Sex and gender sensitive inquiry is critical in pharmaceutical policy due to the sector’s historical
connection with women’s health issues and due to the confluence of biological, social, political, and economic
factors that shape the development, promotion, use, and effects of medicinal treatments. A growing number of
research bodies internationally have issued laws, guidance or encouragement to support conducting sex and
gender based analysis (SGBA) in all health related research.
Methods: In order to investigate the degree to which attempts to mainstream SGBA have translated into actual
research practices in the field of pharmaceutical policy, we employed methods of literature scoping and mapping.
A random sample of English-language pharmaceutical policy research articles published in 2008 and indexed in
MEDLINE was analysed according to: 1) use of sex and gender related language, 2) application of sex and gender
related concepts, and 3) level of SGBA employed.
Results: Two thirds of the articles (67%) in our sample made no mention of sex or gender. Similarly, 69% did not
contain any sex or gender related content whatsoever. Of those that did contain some sex or gender content, the
majority focused on sex. Only 2 of the 85 pharmaceutical policy articles reviewed for this study were primarily
focused on sex or gender issues; both of these were review articles. Eighty-one percent of the articles in our study
contained no SGBA, functioning instead at a sex-blind or gender-neutral level, even though the majority of these
(86%) were focused on topics with sex or gender aspects.
Conclusions: Despite pharmaceutical policy’s long entwinement with issues of sex and gender, and the
emergence of international guidelines for the inclusion of SGBA in health research, the community of
pharmaceutical policy researchers has not internalized, or “mainstreamed,” the practice. Increased application of
SGBA is, in most cases, not only appropriate for the topics under investigation, but well within the reach of today’s
pharmaceutical policy researchers.
Background
Health researchers are increasingly investigating the
ways that social and biological factors interact as deter-
minants of health. The influences of biological and
social dimensions of sex and gender are important in
this regard. Although medical research has historically
focused on issues related to sex (the biological attributes
linked to the categories of male and female) rather than
gender (the social constructs culturally linked to
“maleness” and “femaleness”) [1,2], a growing body of
research suggests that health status, access to care, and
medical outcomes are influenced by an individual’ss t a -
tus in society, including one’s status as a sexed and gen-
dered being [3]. Similar to race and ethnicity studies,
high-quality sex and gender based analysis (SGBA) can
help document inequities in health and health care,
advance understanding of needs, and improve popula-
tion and individual health outcomes. This potential for a
more sophisticated understanding of health needs and
outcomes within and among identified demographic
groups - such as men and women - is greater still when
researchers apply intersectional analysis techniques,
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SGBA may be defined as, “an approach to research and
evaluation which systematically inquires about biological
(sex-based) and sociocultural (gender-based) differences
between women and men, boys and girls, without pre-
suming that any differences exist” [4]. Sex and gender
sensitive inquiry is particularly critical in areas of
pharmaceutical policy due to the sector’s historical
connection with women’s health issues and due to the
confluence of biological, social, political, and economic
factors that shape the development, promotion, use, and
effects of medicinal treatments [4,5]. The women’s health
movement has successfully advocated for more research
on women’s health [6,7], and particularly for women’s
inclusion in clinical trials [8,9], resulting in 1993 United
States legislation [10] and 1997 Canadian guidelines [11]
on inclusion of women in drug trials. A growing number
of research bodies internationally have also issued gui-
dance and encouragement to support conducting “gender
and sex-based analysis” [12] or “gender mainstreaming”
[13] in all health related research.
While the value of high-quality SGBA in pharmaceuti-
cals has been established, it is as yet unclear whether
SGBA has permeated the field of pharmaceutical policy
research. Have the attempts to mainstream SGBA trans-
lated into sex and gender sensitive research practices in
the field of pharmaceutical policy? In order to address
this question, we undertook a literature scoping exercise
to map the extent, range and nature of current practices
related to SGBA in a representative sample of English
language pharmaceutical policy research.
Methods
We employed methods of literature scoping and map-
ping [14-16], beginning with a search of the MEDLINE
database (daily update, 1950-present, via Ovid SP inter-
face) conducted by DG on July 16, 2009 for English lan-
guage articles on pharmaceuticals and public policy that
were published in 2008 (see Appendix 1 for search strat-
egy). Abstracts of potentially relevant citations were
screened by DG for pharmaceutical policy relevance,
defining pharmaceutical policy as, “the rules, processes,
and structures that are put in place by governments and
public agencies to manage problems related to the avail-
ability of medicines and the role of medicine in health
care” [17]. We excluded articles not directly related to
pharmaceutical policy (such as those on illicit drug pol-
icy or environmental health) and non-policy articles on
pharmaceuticals (such as clinical studies of a particular
drug), as well as articles not containing original research
or review content. After screening citations, we drew a
random sample of articles for detailed analysis and
classification.
DG and AB coded the sample of included articles
using a standardized extraction and classification tem-
plate. This template was developed through an iterative
process in which themes from the literature on SGBA
and pharmaceuticals were transformed into coding cate-
gories applicable to a wide range of pharmaceutical pol-
icy research, and pilot tested on a separate sample of
articles from the core journal Health Policy in order to
achieve >90% inter-rater reliability before proceeding
through the included studies. Disagreements in coding
of included studies were reconciled via discussion
between the coders. The template allowed for categori-
cal coding of each article’s research methods and data
sources, binary coding of details about whether and how
s e xa n d / o rg e n d e rw a su s e di nb o t ht h el a n g u a g ea n d
concepts applied in the article, and categorical coding of
the level of SGBA employed in the article. In addition,
the template provided a free text section to capture
additional aspects of interest - ranging from contextual
information that might lend insight into the SGBA
choices of the authors (for example, special attributes of
the data or population studied), to notes on ways SGBA
might have been, but was not, included.
We coded articles’ sex or gender language in terms of
the use of words indicating sex or gender in the text of
the article, for example a statement that “ male survey
r e s p o n d e n t sw e r em o r el i k e l yt os t r o n g l ya g r e e“ or
“46% of the study sample were women.” We also coded
for language that was related to, but not synonymous
with, sex and gender, such as sexual orientation and
pregnancy status. We coded for sex or gender applica-
tion referring to use of sex or gender concepts in the
underpinnings or research analysis of an article; for
example a statistical analysis using sex disaggregated
data, or the consideration of gender norms in a policy
analysis. The intent of this coding was to assess the
extent to which any sex or gender language and concept
use was taking place in our sample. While language and
content of an article are related, it is possible for an arti-
cle to make mention of sex or gender yet not apply it in
any way conceptually or analytically, or to use language
that does not accurately represent the concepts being
applied or investigated; therefore examination of both
among articles in our sample was necessary.
Beyond assessing language and conceptual inclusion of
sex and gender, we assessed whether the studies in our
sample replicated themes commonly identified in the lit-
erature as challenges to achieving “mainstreamed” gen-
der and sex analyses. We coded whether “sex” or
“gender” were defined, and whether sex and gender
were used interchangeably or otherwise conflated. For
articles using quantitative research methods, we coded
whether sex and/or gender was a variable in analysis,
whether the analysis was sex disaggregated, and - if
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women as well as men - whether at least 45% of the
population studied was female. For qualitative studies,
we coded whether or not sex and/or gender were con-
sidered by the study authors as a theme of the analysis.
Finally, adapting Varcoe, Hankivsky, and Morrow’s
hierarchy of “Four approaches to thinking about
women’sh e a l t h ” [18], we coded articles as to the level
of SGBA at which they functioned. Level 1 is the gen-
der-neutral or sex-blind approach, in which sex and
gender are ignored or seen as irrelevant to health. Level
2 comprises approaches reliant on biological essential-
ism or determinism. Level 3 is the level at which sex
and/or gender based analysis is applied, and sex and/or
gender are viewed as significant determinants of health
beyond reproductive and sexual capacity alone. Level 4
includes research in which sex and gender are incorpo-
rated into intersectional analysis, which views sex and
gender as interdependent with other social determi-
nants, such as socio-economic status, culture, sexual
orientation, age, and dis/ability. We flagged Level 1 arti-
cles for which SGBA could reasonably be excluded
based on the study subject, for example economic stu-
dies of competition between firms or policy analyses
about non-gendered phenomena. Studies with human
data and studies of drug or policy impacts on humans
were ineligible to be considered to appropriately func-
tion in a gender-neutral and sex-blind manner.
Results
Articles
Our original search of the MEDLINE database produced
1,346 unique citations published in 2008 and potentially
related to pharmaceuticals and public policy. Title and
abstract reviews reduced the list of potential articles for
our study to 302. We drew a random sample of 151 of
these (50%) for full text analysis. Upon full text analysis,
66 further articles were excluded on the basis of being
off-topic, not including original research, or being una-
vailable in English. The remaining 85 original research
articles about pharmaceutical policy were subject to full
data extraction and classific a t i o n ;1 4o ft h e s ea r t i c l e s
used qualitative research methodologies, 28 used quanti-
tative methods, 40 were review articles, and 3 were the-
ory pieces. Figure 1 illustrates the search and screening
process.
Use of sex and gender language
Table 1 summarizes aspects of sex and gender language
and application in the 85 articles included in our study.
Fifty-seven of the articles (67% of the total) made no
mention of sex or gender. Of those containing some sex
or gender language, 11 articles (13%) mentioned sex,
8 articles (9%) mentioned gender, and 21 articles (25%)
used language that was sex or gender related but not
clearly one or the other. Of the 21 studies using sex
and/or gender language that was ambiguous, the poten-
tially related language focused on concepts such as preg-
nancy, hormones, transsexuals, or women, without
clarity on whether the concepts were intended to be
understood in terms of the biology of sex, social dimen-
sions of gender, or both. None of the papers in our sam-
ple offered a definition of sex or gender, and 7 articles
(8%) used the words sex and gender interchangeably or
otherwise conflated their meaning.
Application of sex and gender concepts
Fifty-nine of the articles in our sample (69% of the total)
contained no sex or gender related content whatsoever,
not even a note that sex or gender data was unavailable
f o rt h a ts t u d y .T h i sn u m b e ri ss l i g h t l yh i g h e rt h a nt h e
number without sex or gender language, as two of these
articles had used sex or gender language somewhere in
the article but did not actually apply any sex or gender
concepts in any part of the article. Of those containing
some level of sex or gender concept application, 18 arti-
cles (21%) included some form of sex-based content,
6 articles (7%) included some form of gender-based con-
tent, and 9 (11%) incorporated related concepts. Some
of these articles applied SGBA to the research that was
the primary focus of the article, whereas others only
included it as part of the article’sc o n c e p t u a lb a c k -
ground or literature review section. Methods and
approaches to applying sex and gender concepts varied
widely within and across study types.
SGBA was the main focus of none of the 5 qualitative
papers [19-23] that considered some aspect of sex,
Potentially relevant articles 
identified and screened by title
n = 1430
Articles to be randomly sorted for 
scoping 
n=302
Full articles retrieved for more in-
depth evaluation
n = 151
Articles mapped according to coding 
rubric 
n = 85
Total articles excluded n = 1128
Duplicate records n=84
Not pharmaceutical policy n=1044
Articles excluded via random sort
n = 151 (50%)
Total articles excluded n = 66
Descriptive or no original data n = 48
Not pharmaceutical policy n = 16
Not available in English n=2
Review 
n=40
Qualitative 
n=14
Quantitative 
n=28
Theory 
n=3
Figure 1 Search and screening process for literature mapping.
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that included some degree of sex content, just 1 [24]
included sex-disaggregated analysis; 3 others [25-27]
used sex as a variable for adjusting/controlling for sex-
related effects (often unspecified). Only 3 [24,25,27] of
all 28 quantitative articles clearly included study popula-
tions that were known to be >45% female, although sev-
eral either did not know or did not disclose the sex
breakdown of human populations studied, so this issue
is difficult to assess in our sample.
Only 2 of the 85 pharmaceutical policy articles
reviewed for this study were primarily focused on sex or
gender issues. Both of these were review articles: one on
the topic of transsexuality treatment options and
another on medical abortion drug approval [28,29].
A third review article [30], focusing on clinical trials
policy, contained a significant focus on sex and gender
issues. All other sex or gender analyses were minor por-
tions of the main articles.
Levels of SGBA
As illustrated in Table 2, 69 (81%) of the studies
included in our analysis conducted research at Level 1, a
gender-neutral or sex-blind approach. Fifty of these arti-
cles (59% of all included studies) took such an approach
even when focusing on topics with possible sex or gen-
der aspects. Quantitative research articles were most
likely to be gender-neutral or sex-blind; however, a
higher proportion of the qualitative studies that took a
Level 1 approach did so when SGBA could reasonably
be expected of the subject matter (79% of Level 1 quali-
tative studies vs. 75% Level 1 quantitative studies).
Ten of our study articles (12%) took a Level 2
approach, either assuming sex and gender by virtue of
focusing on a sexual or reproductive-related topic, or by
equating men or women’s health with gendered body
parts, conditions or therapies (e.g., breasts, pregnancy,
or sildenafil). Six of our study articles (7%) took a Level
3 approach, employing some sort of SGBA in the work
reported. None of the articles employing qualitative
research methods - the methods with perhaps the great-
est potential for capturing rich gender data and concepts
- conducted sex or gender based analysis at this third
level. No articles in our sample employed intersectional
analysis (Level 4).
Data Sources
While the data types and sources utilized by articles in
our sample were diverse (table 3), there did not appear
to be any particular type of data that corresponded with
increased or improved SGBA. Among the qualitative
articles, the three that employed a Level 2 approach to
SGBA, rather than Level 1, utilized all three data types:
legal documents, policy documents, and interviews. The
quantitative article that used a Level 2 approach linked
clinical trial data with drug adverse effect and medical
services data, while the one functioning at the third
level was based on survey data. Use of aggregate data
that prohibited sex- or gender-disaggregated analysis
was common in our sample. The aggregate data phe-
nomenon was especially prominent within the articles
employing quantitative methodologies.
Discussion
Limitations and Interpretation
Results from this scoping and mapping study are not
necessarily representative of all pharmaceutical policy
research. MEDLINE is an incomplete index of the
world’s pharmaceutical policy research, both geographi-
cally and in terms of subject coverage. We further lim-
ited our scope by including only English-language
articles, and only articles from 2008. While this limited
Table 1 Sex and gender language and application by research type among articles included in study
Qualitative articles
(n = 14)
Quantitative articles
(n = 28)
Review articles
(n = 40)
Theory articles
(n = 3)
Total (n = 85)
Sex/gender conflation 0% (0) 7% (2) 10% (4) 33% (1) 8% (7)
Language
Gender 7% (1) 7% (2) 10% (4) 33% (1) 9% (8)
Sex 0% (0) 14% (4) 18% (7) 0% (0) 13% (11)
Related/Ambiguous* 36% (5) 11% (3) 30% (12) 33% (1) 25% (21)
None 64% (9) 75% (21) 63% (25) 67% (2) 67% (57)
Application
Gender 7% (1) 0% (0) 10% (4) 33% (1) 7% (6)
Sex 21% (3) 21% (6) 20% (8) 33% (1) 21% (18)
Related/Ambiguous** 14% (2) 4% (1) 13% (5) 33% (1) 11% (9)
None 64% (9) 75% (21) 68% (27) 67% (2) 69% (59)
* Related/Ambiguous language focused on concepts such as women, pregnancy, hormones, and transsexuals.
** Related/Ambiguous application included such concepts as: pregnancy, sex hormones, gender identity, sexuality, and sexual orientation.
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available, the time-limited sample will necessarily reflect
trends and events of current interest in 2006-2008. By
applying data abstraction and mapping, rather than in-
depth qualitative content analysis, our assessment may
not reflect nuances of the discourse around sex and
gender in the articles we sampled. An in-depth qualita-
tive content analysis of articles in this discipline might
shed further light on the nature of inclusion or exclu-
sion of SGBA in this body of research. Likewise, a larger
statistically-based study might be able to test for differ-
ences among methodological approaches, study coun-
tries of origin, or other article attributes, in order to
further assess the status of SGBA in the field.
Nonetheless, our results reinforce previous assess-
ments that SGBA implementation has not been terribly
successful to date [31,32], even in areas of medicine in
which sex and gender have emerged as significant fac-
tors [33,34]. They also highlight windows of opportunity
for implementing better SGBA in pharmaceutical policy
research. In some cases, incorporating SGBA on the
third level of the four-approaches model is fairly “low
hanging fruit.” Examples of article types that may move
fairly easily from a sex and gender blind approach to a
SGBA approach include qualitative and quantitative stu-
dies that draw on interview, focus group or survey data
collected for the purpose of the project. Yet, we found
no indication that uptake of SGBA was higher among
articles utilizing these data types. Similarly, quantitative
studies relying on administrative data that presumably
contained an individual-level sex field were not particu-
larly likely to conduct sex-stratified analysis.
A minority of pharmaceutical policy issues and research
questions do not necessarily tie in with sex and gender
issues. Studies distanced from human impacts - e.g., about
attributes of published articles, about drug firm beha-
viours, or about economic incentives for drug develop-
ment - may be legitimately considered unlikely to have
sex- or gender-specific effects that should be examined in
the same article. However, studies with human data, stu-
dies of human reactions to drugs, and studies of policy
impacts on humans can all be reasonably expected to
include SGBA. We found many such articles in the Level
1 category lacking SGBA despite discussing a topic known
to have sex and/or gender effects, determinants or dispro-
portionate impacts. Thus, it appears that the field of phar-
maceutical policy has not fully integrated SGBA guidelines
and recommendations into current research practice. In
some cases, it would seem that a higher awareness of sex
and gender issues among pharmaceutical policy research-
ers could make such inclusions second nature. However,
given that discussions of mainstreaming gender and sex
issues into research have been ongoing for many years
now, and major research funders offer guidelines on how
to conduct such research, it is clear that simple “aware-
ness” is not the only thing lacking.
Disciplinary Culture Change Opportunities
By failing to consistently apply SGBA in pharmaceutical
policy research, we risk incomplete or inaccurate research
conclusions about this important component of health
care. However, the field of pharmaceutical policy (and
health policy studies more generally) might borrow from
patient safety literature and frame this as a “systems” defi-
ciency [35]. Rather than blaming individual researchers
Table 2 Levels of SGBA found among articles in study sample
Level 4:
Inter-
sectional
Level 3:
SGBA
applied
Level 2:
Biological
essentialism/
determinism
Level 1: Gender-
neutral or sex-blind
Level 1: SGBA
reasonably excluded
Level 1: SGBA
reasonably expected
Qualitative articles 0 (0%) 0 (0%) 3 (21%) 11 (79%) 0 (0%) 11 (79%)
Quantitative articles 0 (0%) 1 (4%) 1 (4%) 26 (93%) 5 (18%) 21 (75%)
Review articles 0 (0%) 4 (10%) 6 (15%) 30 (75%) 13 (33%) 17 (43%)
Theory articles 0 (0%) 1 (33%) 0 (0%) 2 (67%) 1 (33%) 1 (33%)
Total 0 (0%) 6 (7%) 10 (12%) 69 (81%) 19 (22%) 50 (59%)
Table 3 Data sources, by research method of article
Qualitative data sources
Legal and/or policy documents (n = 10)
Focus groups or interviews (n = 4)
Quantitative data sources *
Administrative prescription database (n = 10)
Drug approval data (n = 7)
Survey data (n = 5)
Clinical study/trial data (n = 4)
Drug safety/adverse event data (n = 3)
Other medical services data (n = 2)
Other data source (n = 4)**
* Categories are not mutually exclusive.
** Other sources include: drug promotion spending, mathematical models,
and various types of drug and drug company information.
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should be placed upon changing the culture of pharma-
ceutical policy researchers. Such an approach of targeting
the culture of researchers, in order to create a social shift,
is supported by Rogers’ Diffusion of Innovation theory
[36], which posits that awareness is merely the beginning
stage of acceptance of a new way of functioning. Beyond
awareness, individuals must be persuaded before deciding
to implement change.
How can pharmaceutical policy researchers be per-
suaded to implement change? Creating a peer culture
that expects to see evidence of SGBA in any paper may
provide “checks” for SGBA in the peer review process
for papers and presentations. Adoption of SGBA as a
routine element in pharmaceutical policy research could
be further facilitated by transforming current health
research funder guidelines and policies, which may be
ignored with little consequence to researchers, into fir-
mer requirements for grant support or renewal. Finally,
were journals, or the International Committee of Medi-
cal Journal Editors, to require SGBA unless inappropri-
ate, this could significantly impact the frequency with
which SGBA appears in the published literature, as
acceptability for publication has been identified as a
motivating factor for other study attributes [37].
In order to illustrate common approaches to SGBA
within contemporary pharmaceutical policy research, we
turn our lens inward by critiquing a selection of papers
produced by our own team. As a coordinating centre of
a national pharmaceutical policy research network, we
conduct studies on a wide variety of policy questions
using varied methods in our work. The following four
selected studies illustrate areas of opportunity for SGBA
and, in some cases, areas where SGBA will be acceptably
limited. In reflecting on our own research and reporting
practices, we find ourselves no less “guilty” of neglecting
SGBA than our colleagues: we have failed to either per-
form or report on sex-disaggregated analyses in quanti-
tative studies, conflated our terminology and failed to
look for gendered aspects of policy phenomena.
The first of our papers is an example of a topic for
which sex and gender aspects are not apparent, as was
the case with a minority of the papers mapped for this
study of the literature. This was a study of the correla-
tion between drug pricing policy and research and
development (R&D) spending [38]. While there may be
definite gendered forces directing R&D expenditures
and dictating reactions to pricing policies, the primary
focus of the study and the data involved do not provide
grounds for necessarily conducting or commenting on
sex and/or gender themes. Thus, while this article works
at Level 1 of the four approaches to SGBA, such an
approach is not inappropriate.
The second example illustrates analysis of sex-specific
concerns without in-depth SGBA. Published as a medi-
cal journal “research letter,” the article examined the
impact of media reports about drug risks on purchases
of a hormonally-based drug by Canadian women [39]. It
reported findings of an empirical analysis of a sex-
specific concern (potentially dangerous off-label
prescribing), but did so without any critical analysis of
gender dynamics. Since the article did not reach beyond
using women’sd a t at os t u d yaw o m e n ’s health issue
related to female reproductive capacities, it might be
considered a Level 2 approach (biological essentialism).
However, we can report from our experience in writing
this article (and others for like journals) that medical
journal articles have strict word limits and must focus
on the (generally clinical) interest of the readership. A
Level 4 (intersectional) study of this topic could be done
- and would be a valuable contribution to scholarship
about gendered dynamics related to medicine use, pro-
motion, risks and harms - but it would not likely be
publishable in a general medical journal.
The third example drawn from our work illustrates
missed opportunities to conduct meaningful SGBA. In a
recent paper published in a health services journal,
researchers compared cost-related nonadherence
(CRNA) to prescription drugs in the United States and
Canada [40]. Findings were adjusted for sex, but analysis
was not sex-stratified. While sex differences in CRNA
were not the primary outcome of interest, given the
mixed evidence on sex or gender as determinants of
nonadherence [41], it would have been ideal to have
also examined this potential phenomenon in this study.
While the study concluded that there is a “Canadian
advantage” in prescription adherence, it would have
been preferable to know if this advantage is gender and
sex neutral or whether it applies more for women or
men. Intersecting sex and income (another factor that
was adjusted for, rather than stratified in the paper),
would go further yet in adding valuable knowledge
about CRNA. Although the survey used for this study
would not have powered the intersectional ideal, the
fact remains that this paper is an example of a study
that should have moved beyond a Level 1 approach or,
if sample size prohibited, commented on the need to do
so in future research.
Power considerations are less likely to be a problem
for research with administrative data, as our final exam-
ple illustrates. In an examination of outpatient prescrip-
tion drug spending, researchers sex-disaggregated the
data but did not explore the interpretation of that analy-
sis [42]. The term “gender” was used throughout the
study but the discussion of results reveals that the study
conflated terms by using “gender” as a euphemism for
“sex.” While this paper met our minimal criteria for a
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results, a fuller SBA would have required additional
tables of the major finding by sex. Moreover, although
the paper explored the effects of sex, income, age, and
health status on financial burdens, it was not a Level 4
approach to SGBA because, like most statistical analyses,
it assessed the individual contributions of these charac-
teristics to the outcome of interest rather than intersect-
ing them.
Conclusions
Via a literature mapping method, we investigated the
use of sex and gender-related language, inclusion of sex
and gender-related concepts, and level of sex and gender
based analysis (SGBA) in a sample of contemporary
English-language pharmaceutical policy research. We
found that the majority of articles could have reasonably
been expected to include SGBA but did not. Despite
pharmaceutical policy’s long entwinement with issues of
sex and gender, and the emergence of international
guidelines for inclusion of sex and gender in health
research, the community of pharmaceutical policy
researchers appears not to have internalized, or “main-
streamed,” gender and sex analyses. While research fun-
ders have adopted SGBA policies, medical journals,
which might have greater influence, have not yet fol-
lowed suit. Increased application of SGBA is, in
most cases, not only appropriate for the topics under
investigation, but well within the reach of today’sp h a r -
maceutical policy researchers. However, this requires
consideration of sex and gender factors in research
design in order to ensure adequate data sources and
analytical frameworks. Fully intersectional analysis,
examining the interactions between sex and gender and
other social determinants of health, is rarely approached
in today’s pharmaceutical policy literature. While this is
unsurprising, given the relative novelty of intersectional
approaches, it should not be seen as prohibitive for
pharmaceutical policy research to begin to employ
methods that grapple with multiple and overlapping
issues of diversity and difference.
Appendix: Search Strategy
MEDLINE 1950-present with daily update (Ovid)
13 July, 2009
1. public policy/or health policy/
2. legislation, drug/or “drug and narcotic control"/or
drug approval.mp.
3. 1 or 2
4. Pharmaceutical Services/or Insurance, Pharmaceuti-
cal Services/or Technology, Pharmaceutical/or Pharma-
ceutical Preparations/or Pharmaceutical Solutions/
5. (Pharmaceutical$ or Prescription or Prescription
Drug$ or Drug$ or Medicine$ or medication$).mp.
6. 4 or 5
7. 3 and 6
8. limit 7 to yr="2008”
9. limit 8 to english language
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